Endocrine Abstracts

A rapidly growing neoplastic mass of the neck can either be caused by an anaplastic thyroid cancer (ATC) or a primitive lymphoma of the thyroid gland (PLT). These two malignancies share the same clinical features but vary widely in their treatment and outcome. Only histologic criteria through biopsy can provide a definitive diagnosis. The aim of this study was to assess biological and radiological differences between ATC and PLT in order to hasten differential diagnosis. Sixty...

The biological diagnosis of pheochromocytoma (P) and/or paraganglioma (Pgg) relies on the identification of excessive secretion of the metanephrines. Chomogranin A (CgA) is a general indicator of neuroendocrine tumours that is highly expressed in P and correlate with tumour mass and secretory activity. The CgA test could be indicated as a useful test in patients with false positive metanephrines results. The aim of our prospective bi-centre study, is to evaluate the performanc...

Introduction: Pheochromocytoma and most abdominal paraganglioma (PPGL) can secrete catecholamines. In vitro and in vivo, catecholamines modulate bone remodeling by stimulating bone resorption. In patients with PPGL, four studies have previously demonstrated an increase of biological markers of bone resorption, a decreased of bone density and a higher prevalence of vertebral fractures. We report two patients with malignant abdominal secreting paraganglioma pre...

Purpose: Bone metastases (BM) are frequent in differentiated thyroid cancer (DTC). These patients may present skeletal-related events (SRE), the leading cause of DTC-related morbidity. We aimed to evaluate the clinical features, treatment approaches, and outcomes including overall survival (OS) of DTC patients with BM complicated by SRE and their evolution over time.Methods: 178 consecutive DTC patients harbouring BM were enrolled in this retrospective s...

Objectives: RET alterations are targetable oncogenic drivers in TC. Patients with TC, especially those with MTC treated with the multikinase inhibitors cabozantinib and/or vandetanib (C/V), often experience significant treatment-related side effects. Pralsetinib, a selective RET tyrosine kinase inhibitor, showed efficacy in patients with RET-altered TC from the phase 1/2 ARROW trial (NCT03037385). We present the impact of pralsetinib on PROs in patients with ...

Purpose: To validate a prognostic stratification system of overall survival (OS) in stage IV pancreatic neuroendocrine tumors (pNETs) naïve of therapy by analyzing 1) prognostic parameters at the time of stage IV diagnosis; 2) the role of spontaneous tumor slope.Patients and Methods: Multicenter retrospective study including consecutive patients diagnosed with stage IV pNET from January 1997 to March 2014. Inclusion criteria were: 1. pNET w...

Propose: To screen for the presence of putative targets for new treatments in a large cohort of advanced adrenocortical cancer (ACC)Experimental design: In 40 adult stage III-IV ACC primary samples, we used comparative genomic hybridization (CGH) and hotspot gene sequencing (with Ion Torrent) to describe the presence of copy number abnormalities and mutations in more than 40 genes involved in cancer development and putative drug sensitivity (HER2; EGFR; ...

Background: Osilodrostat is a potent oral inhibitor of the adrenal enzymes aldosterone synthase and 11b-hydroxylase and decreases glucocorticoid and mineralocorticoid production and secretion. Phase 2 and 3 studies from the osilodrostat clinical trial programme have demonstrated the drug’s efficacy and safety in patients with Cushing’s disease. Osilodrostat received European Marketing Authorization (MA) for the treatment of Cushing’s syndrome (CS) in adults....